Bristol Myers Squibb (BMY) Change in Cash (2009 - 2026)

Bristol Myers Squibb has disclosed Change in Cash across 18 years of filings, most recently posting -$635.0 million for Q1 2026.

• In Q1 2026, Change in Cash fell 220.27% year-over-year to -$635.0 million; the TTM figure through Mar 2026 stood at -$1.3 billion (down 183.84% YoY), while the FY2025 annual figure was -$129.0 million, up 88.99% from the prior year.
• Change in Cash improved to -$635.0 million in Q1 2026, from -$5.5 billion in the prior quarter.
• Over the last five years, Change in Cash for BMY reached as high as $4.0 billion in Q4 2023 and fell as low as -$5.5 billion in Q4 2025.
• The 5-year median for Change in Cash is -$623.0 million (2023), against an average of -$278.4 million.
• Annual changes were most pronounced in 2022 — Change in Cash tumbled 2230.26% — and 2024, when it surged 286.35%.
• A 5-year view of Change in Cash shows it stood at $1.4 billion in 2022, then jumped by 188.82% to $4.0 billion in 2023, then sank by 37.89% to $2.5 billion in 2024, then sank by 324.45% to -$5.5 billion in 2025, then surged by 88.47% to -$635.0 million in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered -$635.0 million, -$5.5 billion, and $3.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.